or Try an Advanced Search...

    Technical Analysis for SABS - SAB Biotherapeutics, Inc.

    Grade Last Price % Change Price Change
    B 3.88 19.02% 0.62
    SABS closed up 19.02 percent on Friday, November 1, 2024, on 2.85 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: Nov 12
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical SABS trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish 0.00%
    Expansion Breakout Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Wide Range Bar Range Expansion 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Older End-of-Day Signals for SABS ...

       Recent Intraday Alerts

    Alert Time
    200 DMA Resistance about 19 hours ago
    Fell Below Upper Bollinger Band about 19 hours ago
    Up 2 ATRs about 20 hours ago
    Rose Above 200 DMA about 20 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SABS Chart by TradingView
    Basic chart:

    Profile

    SAB Biotherapeutics, Inc. Description

    SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Pharmaceutical Immunology Immune System Immunotherapy Infectious Diseases Diabetes Autoimmune Disease Antibodies Antibody Immunotherapies Influenza Genetic Engineering Us Government Human Diseases Transplantation Glycoproteins Polyclonal Antibodies Type 1 Diabetes

    Is SABS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
    Sep 23 SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
    Sep 13 SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
    Sep 9 SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
    Sep 4 SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
    Aug 9 SAB Biotherapeutics GAAP EPS of -$0.79
    Aug 8 SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
    Aug 5 SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
    Jul 31 SAB Biotherapeutics names Lucy To as CFO
    Jul 31 SAB BIO Appoints Lucy To as Chief Financial Officer
    See more SABS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 10.0
    52 Week Low 2.16
    Average Volume 72,674
    200-Day Moving Average 3.68
    50-Day Moving Average 2.80
    20-Day Moving Average 2.85
    10-Day Moving Average 3.02
    Average True Range 0.31
    RSI (14) 70.67
    ADX 22.75
    +DI 37.49
    -DI 9.98
    Chandelier Exit (Long, 3 ATRs) 3.05
    Chandelier Exit (Short, 3 ATRs) 3.29
    Upper Bollinger Bands 3.51
    Lower Bollinger Band 2.19
    Percent B (%b) 1.28
    BandWidth 46.51
    MACD Line 0.16
    MACD Signal Line 0.06
    MACD Histogram 0.0951
    Fundamentals Value
    Market Cap 35.79 Million
    Num Shares 9.23 Million
    EPS -5.60
    Price-to-Earnings (P/E) Ratio -0.69
    Price-to-Sales 13.45
    Price-to-Book 3.28
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.96
    Resistance 3 (R3) 4.87 4.43 4.78
    Resistance 2 (R2) 4.43 4.15 4.47 4.72
    Resistance 1 (R1) 4.15 3.98 4.29 4.24 4.66
    Pivot Point 3.71 3.71 3.77 3.75 3.71
    Support 1 (S1) 3.43 3.43 3.57 3.52 3.10
    Support 2 (S2) 2.99 3.26 3.03 3.04
    Support 3 (S3) 2.71 2.99 2.98
    Support 4 (S4) 2.80